Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms

New migraine data builds on prior clinical studies in depressionHOUSTON, Aug. 07, 2023 -- Nexalin Technology, Inc. today provided an update on the growing body of clinical data supporting the...

Related Keywords

United States ,Houston ,Texas ,China ,Zhengzhou ,Henan ,Nexalin Gen ,Mark White ,Chinj Neuromed ,Exchange Commission ,Nexalin Technology Inc ,Nexalin Technology ,Wider Come Limited ,United States Department Of Health ,Company Or Nexalin Nasdaq ,Vertigo Center ,World Health Organization ,Company Report On Form ,Second Affiliated Hospital Of Zhengzhou University ,Crescendo Communications ,Company Gen ,National Medical Products Administration ,Department Of Neurology ,Human Services ,Second Affiliated Hospital ,Visual Analog Scale ,Pittsburgh Sleep Quality Index ,Hamilton Anxiety Rating Scale ,Hamilton Depression Rating Scale ,Migraine Specific Quality ,Life Questionnaire ,United States Department ,Risk Factors ,Markets ,